Cargando…
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
OBJECTIVES: Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post...
Autores principales: | Felten, Renaud, Widawski, Laura, Spielmann, Lionel, Gaillez, Corine, Bao, Weibin, Gottenberg, Jacques-Eric, Duret, Pierre-Marie, Messer, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649802/ https://www.ncbi.nlm.nih.gov/pubmed/37945285 http://dx.doi.org/10.1136/rmdopen-2023-003428 |
Ejemplares similares
-
Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat
por: Widawski, L., et al.
Publicado: (2022) -
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022) -
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021) -
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
por: Álvaro-Gracia, José M, et al.
Publicado: (2023) -
Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)